Analysts Set Bruker Co. (NASDAQ:BRKR) PT at $70.50

Bruker Co. (NASDAQ:BRKR) has been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are presently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $70.50.

BRKR has been the topic of a number of recent analyst reports. Stifel Nicolaus dropped their price target on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a report on Friday, February 14th. Bank of America lifted their price target on Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Wells Fargo & Company lowered their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Citigroup reduced their target price on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Barclays reduced their price objective on Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th.

Institutional Investors Weigh In On Bruker

Large investors have recently added to or reduced their stakes in the stock. True Wealth Design LLC boosted its holdings in shares of Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after purchasing an additional 510 shares during the period. Eagle Bay Advisors LLC boosted its stake in Bruker by 2,324.1% during the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after buying an additional 674 shares during the period. UMB Bank n.a. increased its position in Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 248 shares during the last quarter. Values First Advisors Inc. bought a new position in Bruker during the third quarter valued at $73,000. Finally, GAMMA Investing LLC raised its stake in shares of Bruker by 47.5% in the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after acquiring an additional 412 shares during the period. 79.52% of the stock is owned by institutional investors.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $52.92 on Friday. The firm’s fifty day moving average is $56.87 and its 200-day moving average is $60.13. Bruker has a 52 week low of $48.07 and a 52 week high of $94.86. The firm has a market cap of $8.02 billion, a PE ratio of 69.63, a price-to-earnings-growth ratio of 2.07 and a beta of 1.16. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Sell-side analysts predict that Bruker will post 2.69 earnings per share for the current year.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.